Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug 15;19(16):3295-301.
doi: 10.1093/hmg/ddq221. Epub 2010 Jun 9.

Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals

Affiliations

Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals

Jason J Corneveaux et al. Hum Mol Genet. .

Abstract

In this study, we assess 34 of the most replicated genetic associations for Alzheimer's disease (AD) using data generated on Affymetrix SNP 6.0 arrays and imputed at over 5.7 million markers from a unique cohort of over 1600 neuropathologically defined AD cases and controls (1019 cases and 591 controls). Testing the top genes from the AlzGene meta-analysis, we confirm the well-known association with APOE single nucleotide polymorphisms (SNPs), the CLU, PICALM and CR1 SNPs recently implicated in unusually large data sets, and previously implicated CST3 and ACE SNPs. In the cases of CLU, PICALM and CR1, as well as in APOE, the odds ratios we find are slightly larger than those previously reported in clinical samples, consistent with what we believe to be more accurate classification of disease in the clinically characterized and neuropathologically confirmed AD cases and controls.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Evans D.A., Funkenstein H.H., Albert M.S., Scherr P.A., Cook N.R., Chown M.J., Hebert L.E., Hennekens C.H., Taylor J.O. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA. 1989;262:2551–2556. doi:10.1001/jama.262.18.2551. - DOI - PubMed
    1. Meyer J.M., Breitner J.C. Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel. Am. J. Med. Genet. 1998;81:92–97. doi:10.1002/(SICI)1096-8628(19980207)81:1<92::AID-AJMG16>3.0.CO;2-R. - DOI - PubMed
    1. Williamson J., Goldman J., Marder K.S. Genetic aspects of Alzheimer disease. Neurologist. 2009;15:80–86. doi:10.1097/NRL.0b013e318187e76b. - DOI - PMC - PubMed
    1. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261:921–923. doi:10.1126/science.8346443. - DOI - PubMed
    1. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA. 1993;90:1977–1981. doi:10.1073/pnas.90.5.1977. - DOI - PMC - PubMed